YB328 Microbiome Program
Cancer Immunotherapy
ResearchClinical application research initiated
Key Facts
Indication
Cancer Immunotherapy
Phase
Research
Status
Clinical application research initiated
Company
About ARC Therapies
National Cancer Center Japan spin-out developing novel cell and gene therapies for oncology, with programs targeting ATLL and microbiome-based immunotherapies.
View full company profileTherapeutic Areas
Other Cancer Immunotherapy Drugs
| Drug | Company | Phase |
|---|---|---|
| CYTER915 | FibroBiologics | Discovery |
| Immuno-Oncology | Resolve Biosciences | Research-Use |
| In vivo CAR-T Program | Deliver Biosciences | Pre-clinical |
| Novel Target Discovery | Noetik | Discovery |
| Engineered Cancer Exosomes (HLA‑G Targeted) | Esco Aster | Preclinical |